| Similar Articles |
|---|
 |
The Motley Fool
December 4, 2006
Brian Lawler |
Success for Dynavax Solid results from the first of three phase III trials cause the biopharmaceutical Dynavax's shares to rise.   |
Nurse Practitioner
December 2009
Gujral & Collantes |
Understanding Viral Hepatitis: A guide for primary care Recent advancements in the field of genomics and proteomics technology have given researchers and clinicians more insight on disease pathogenesis and helped create more tailored approaches to the treatment of these conditions. |
The Motley Fool
January 3, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Telik... Gorman-Rupp... China Netcom... Penson Worldwide... |
The Motley Fool
January 24, 2007
Matt Koppenheffer |
The 5-Sigma Report These stocks experienced serious volatility in the past week: Mills... Rackable Systems... Genesis HealthCare... GPC Biotech... Total System Services... |
The Motley Fool
March 18, 2008
Brian Orelli |
Dynavax Gets Held Up The FDA puts a clinical hold on Dynavax Technologies hepatitis B vaccine. Investors, take note. |
The Motley Fool
February 28, 2007
Brian Lawler |
Dynavax Down but Not Out Drug developer Dynavax gives guidance for 2007 after its lead drug candidate fails in clinical testing. |
The Motley Fool
January 31, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that experienced serious volatility last week. 21st Century Insurance Group... LECG... Novelis... National Interstate Group... Technitrol... |
The Motley Fool
January 11, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Semiconductor Manufacturing International... Herbalife... New York & Company... Atherogenics... Hot Topic... |
The Motley Fool
July 21, 2011
Brian Orelli |
Does Dynavax Need a Do-Over? The FDA won't be smiling at its data. |
The Motley Fool
March 20, 2007
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Accredited Home Lenders... Newcastle Investment... NovaStar Financial... Fremont General... American Oriental Bioengineering... |
American Family Physician
November 1, 2001
Thomas R. Riley |
Preventive Strategies in Chronic Liver Disease Chronic liver disease is the 10th leading cause of death in the United States. Preventive care can significantly reduce the progression of liver disease. Part I: Alcohol, Vaccines, Toxic Medications and Supplements, Diet and Exercise... |
The Motley Fool
November 29, 2006
Matt Koppenheffer |
The 5-Sigma Report In a 5-sigma move, a stock has a one-day price move that is five standard deviations or more from the stock's average one-day change. Here are more stocks that defy the averages. Blockbuster... J Crew Group... etc. |
The Motley Fool
December 12, 2006
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Gallaher Group... Kyphon... Vanda Pharmaceuticals... Bank of New York... Pfizer... |
The Motley Fool
July 19, 2007
Emil Lee |
US Bancorp's Masked Momentum Amid a tough environment, the bank awaits its chance to shine. It doesn't take a Harvard MBA to figure out that the market might be undervaluing the company. |
